ライフサイエンスコーパス: A2 receptor

1 tent with the activation of ocular adenosine A2 receptors.

2 lly reversed by blockade of adenosine A1 and A2 receptors.

3 .g., human platelet thrombin and thromboxane A2 receptors.

4 increase in Galphaq coupling to thromboxane A2 receptors.

5 n increase in ligand affinity of thromboxane A2 receptors.

6 tinguishable from human platelet thromboxane A2 receptors.

7 may mediate the desensitization of adenosine A2 receptors.

8 podocyte antigens: the M-type phospholipase A2 receptor 1 (PLA2R) and thrombospondin type 1 domain-c

9 Phospholipase A2 receptor 1 (PLA2R) is a target autoantigen in 70% of

10 jor target antigen, the M-type phospholipase A2 receptor 1 (PLA2R).

11 the podocyte surface antigens phospholipase A2 receptor 1 (PLA2R1) and the recently identified throm

12 ith autoantibodies against the phospholipase A2 receptor 1 (PLA2R1).

13 ) along with the major antigen phospholipase A2 receptor 1 (PLA2R1).

14 ntibodies targeting the M-type phospholipase A2 receptor-1 (PLA2R) on the surface of glomerular visce

15 the ortholog of the mammalian phospholipase A2 receptor, a mannose receptor family member, rather th

16 DPMA, an adenosine A2 receptor (A2R) agonist, decreased KDR mRNA in a dose-

17 imulatory concentrations; however, adenosine A2 receptor (A2R) agonists DPMA, NECA, and CGS21680 incr

18 5'-(N-ethylcalboxamido)-adenosine (adenosine A2 receptor [A2R] agonists, Kd = 15 and 16 nmol/l, respe

19 on of PKC can block the effects of adenosine A2 receptor activation by CGS-21680 on anoxia and reoxyg

20 A1 receptor activation, the implications of A2 receptor activation on synaptic transmission have not

21 d which inhibits neutrophil function through A2 receptor activation.

22 The adenosine A2 receptor agonist 5'-(N-cyclopropyl)-carboxamidoadenos

23 stimulated O2.- generation by the adenosine A2 receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA

24 The selective adenosine A2 receptor agonist DPMA (10 micromol/L) decreased TNF-a

25 an platelets by thrombin and the thromboxane A2 receptor agonist U46619 lead to phosphorylation of Ga

26 vasoconstriction induced by the thromboxane A2 receptor agonist U46619, which suggest a NO-independe

27 enosine (CGS-21680 [20 nmol/L], an adenosine A2 receptor agonist, R-(--)-N6-(2-phenylisopropyl)-adeno

28 ated by adenosine (10 microM, 2 min) and the A2-receptor agonist 2-p-(2-carboxyethyl)phenethylamino-5

29 The effect appears to be mediated by the A2 receptor and transduced through a G protein-adenylyl

30 demonstrated expression of the phospholipase A2 receptor and two G-protein-coupled receptors for LPC

31 y requires adenosine activation of adenosine A2 receptors and is mediated by beta gamma dimers.

32 acting to increase O2 delivery via adenosine A2 receptors and to decrease metabolic rate via A1 recep

33 In contrast, a highly specific A2 receptor antagonist (10(-7) or 10(-5) M) had no effec

34 yl-1, 3-dipropylxanthine (DPCPX) but not the A2 receptor antagonist 3, 7-dimethyl-1-propargylxanthine

35 or inhibition of adenosine by the adenosine A2 receptor antagonist 3,7-dimethyl-1-propargylxanthine

36 nists and AP-5 were reversed by an adenosine A2 receptor antagonist administered intraperitoneally.

37 lished by administration of the adenosine A1/A2 receptor antagonist PD 115,199 (3 mg/kg i.v.) before

38 Aspirin and the thromboxane A2 receptor antagonist SQ29548 inhibited activation of t

39 After pretreatment with the thromboxane A2 receptor antagonist SQ30, 741, the vasoconstrictor re

40 ected by 3,7-dimethy-1-propargylxanthine, an A2 receptor antagonist.

41 se of ticagrelor followed by an adenosine A1/A2-receptor antagonist [8-(p-sulfophenyl)theophylline, 4

42 ase, in the presence of the adenosine A1 and A2 receptor antagonists 8-cyclopentyl-1,3-dipropylxanthi

43 r agonist CGS-21680 (50% closure by day 2 in A2 receptor antagonists.

44 of L-arginine transport was inhibited by the A2-receptor antagonists ZM-241385 and 3,7-dimethyl-1-pro

45 hyl ester (an NO synthase inhibitor) and the A2-receptor antagonists ZM-241385 and DMPX prevented inc

46 circulating nephritogenic anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies and genetic poly

47 P = 0.010] and those with anti-phospholipase A2 receptor antibodies [hazard ratio = 3.761 (1.635-8.65

48 Rates of antiphospholipase A2 receptor antibody (anti-PLA2R-Ab) depletion in NIAT-r

49 active against a polyclonal anti-thromboxane A2 receptor antibody.

50 riments tested the hypothesis that adenosine A2 receptors are involved in central reward function.

51 A2 receptor blockade by the A2 antagonist, DMPX (3,7-dim

52 A2 receptor blockade in the presence of complete A1 rece

53 nase inhibition with aspirin and thromboxane A2 receptor blockade with ifetroban on the chronic vasod

54 D2 or adenosine A2 receptor blockade, pertussis toxin, Rp-cAMPS, or over

55 EP4, prostaglandin F2alpha, and thromboxane A2 receptors but not anti-inflammatory EP2, prostaglandi

56 onists, including caffeine, or targeting the A2 receptors by siRNA pretreatment of T cells improved t

57 uency test pulses (0.033 Hz) indicating that A2 receptors can enhance synaptic transmission.

58 Agents active at A2 receptors either were without effect or could be bloc

59 The erythropoietin-producing hepatoma A2 receptor (EphA2) is a tyrosine kinase overexpressed b

60 nd activation of the signal molecules ephrin-A2 receptor, FAK, Src, and Rac1.

61 ntegrin molecules and tyrosine kinase ephrin-A2 receptor, followed by the activation of preexisting i

62 A2 receptors for extracellular adenosine might act as bo

63 ate the presence of a functional thromboxane A2 receptor in oligodendrocytes and are consistent with

64 ons indicating a high density of thromboxane A2 receptors in myelinated brain and spinal cord fiber t

65 The presence of functional thromboxane A2 receptors in neonatal rat oligodendrocytes and human

66 The human platelet thromboxane A2 receptor is a member of the G-protein-coupled superfa

67 Together, these results suggest that the A2 receptors may play an important role in the induction

68 the protective effects of adenosine include A2-receptor mediated vasodilation, A1-receptor mediated

69 y of the novel antagonist N-0861, the A1 and A2 receptor-mediated cardiac effects of adenosine were i

70 8-chlorostyrylcaffeine (CSC), suggesting an A2 receptor-mediated mechanism.

71 nstriction in vivo, which is often masked by A2 receptor-mediated vasodilation.

72 ine diminishes inflammation via occupancy of A2 receptors on inflammatory cells.

73 The phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-con

74 The characterization of the phospholipase A2 receptor (PLA2R) as the major target antigen in prima

75 Phospholipase A2 receptor (PLA2R) is a member of the mannose receptor

76 The M-type phospholipase A2 receptor (PLA2R) is expressed in podocytes in human g

77 Secretory phospholipase A2 receptor (PLA2R) is the target antigen of the auto-an

78 ht to determine the utility of phospholipase A2 receptor (PLA2R) staining for the detection of recurr

79 ve IgG4 autoantibodies against phospholipase A2 receptor (PLA2R).

80 ing IgG4 autoantibodies to the phospholipase A2 receptor (PLA2R).

81 ic variants in an HLA-DQA1 and phospholipase A2 receptor (PLA2R1) allele associate most significantly

82 The phospholipase A2 receptor (PLA2R1) is the major autoantigen in idiopat

83 The phospholipase A2 receptor (PLA2R1) is the major autoantigen in primary

84 out the biological role of the phospholipase A2 receptor (PLA2R1) transmembrane protein.

85 the physiological role of the phospholipase A2 receptor (PLA2R1).

86 We examined the role adenosine A2 receptors play in the efficacy of neurotransmission b

87 45 min following the tetanus indicating that A2 receptors play no significant role in the maintenance

88 racellular cAMP levels through activation of A2 receptors present on developing amacrine and ganglion

89 tion as the second intron of the thromboxane A2 receptor, prostaglandin D2 receptor, prostaglandin I2

90 he effects of adenosine and adenosine Al and A2 receptor subtype agonists on in vitro perfused contro

91 creases Galphaq association with thromboxane A2 receptors thereby shifting them to a higher affinity

92 probably mediated by activation of adenosine A2 receptors through the PKC pathway, and (3) the preser

93 from astrocytes by a direct effect on A1 and A2 receptors, thus providing a link between actions of N

94 HHV-8 uses langerin and the ephrin A2 receptor to infect Langerhans cells, which support fu

95 vasodilatation, and stimulates carotid body A2 receptors to increase respiration.

96 eased by acute hypoxia stimulates A1 but not A2 receptors to produce muscle vasodilatation, and stimu

97 F2alpha receptor (FP) (61), and thromboxane A2 receptor (TP) (11) while sparing EP2, EP3, and prosta

98 he PGF2 alpha receptor (FP), the thromboxane A2 receptor (TP) and the prostacyclin receptor (IP).

99 lexibility of the purified human thromboxane A2 receptor (TP) was characterized by spectroscopic appr

100 Human thromboxane A2 receptor (TP), a G protein-coupled receptor (GPCR), i

101 date the molecular mechanisms of thromboxane A2 receptor (TP)-induced insulin resistance in endotheli

102 Here, we show that vasopressive thromboxane A2 receptors (TP) can intimately couple with and inhibit

103 We explore here, using the thromboxane A2 receptor TPalpha, the ability of G12 and G13 to repor

104 tors; two splice variants of the thromboxane A2 receptor (TPalpha and TPbeta) have been cloned.

105 n of the signaling properties of thromboxane A2 receptor (TPalpha) -Galpha12 and -Galpha13 fusion con

106 g partner of the beta-isoform of thromboxane A2 receptor (TPbeta) by yeast two-hybrid screening.

107 Thromboxane A2 receptor (TPr) stimulation induces cellular hypertrop

108 oxidative stress, activates the thromboxane A2 receptor (TXAR) and the Rho-associated kinase (ROCK)

109 ing effect could be mediated by an adenosine A2 receptor via the protein kinase C (PKC) pathway.

110 elated, but distinct, X-linked ectodysplasin-A2 receptor (XEDAR).